title: Fuzhengpaidu granule regulates immune activation molecules CD38 and human leukocyte antigen-D related on CD4+ and CD8+ T cells in patients with acquired immunodeficiency syndrome/human immunodeficiency virus.
abstract: OBJECTIVE
  To evaluate the effect of Fuzhengpaidu granule (FZPDG) on immune activation molecules CD38 and human leukocyte antigen-D related (HLA-DR) on CD4+ and CD8+ cells in HIV/AIDS patients, and to explore the underlying mechanism of this therapy.
  
  
  METHODS
  Plasma changes in CD3+, CD4+, CD8+, CD3 + CD4 + CD38 +, CD3 + CD4 + HLA-DR+, CD3 + CD8+CD38+, and CD3+CD8+HLA-DR+ levels in HIV/ AIDS patients treated with FZPDG for six months were examined by flow cytometry and compared with levels in healthy controls.
  
  
  RESULTS
  The clinical trial included 34 outpatients with HIV/AIDS. Before treatment, plasma levels of CD38+ and HLA-DR+ on CD4/CD8 cells were higher than those in 28 health controls (P < 0.05). There were no significant changes in serum levels of CD3+, CD4+, and CD8+ T cells between pretreatment baseline versus after treatment, which were 82.85% +/- 5.41%, 14.57% +/- 10.31% and 54.55% +/- 11.43% before treatment and 79.15% +/- 8.21%, 19.96% +/- 9.58% and 56.36% +/- 11.67% after treatment, respectively (P > 0.05). Plasma levels of CD3+ CD4+CD38+ and CD3+CD4+HLA-DR+ were 2.3% +/-2.2% and 7.8% +/- 5.5% before treatment and 1.2% +/-0.8% and 2.6% +/- 1.0% after treatment, respectively. Plasma levels of CD3+CD8+CD38+ and CD3+CD8+ HLA-DR+ were 41.4% +/- 13.4% and 17.8% +/- 11.3% before treatment, which changed to 27.1% +/- 10.2% and 3.8% +/- 2.4% after treatment, respectively (P < 0.05).
  
  
  CONCLUSIONS
  HIV/AIDS patients exhibited an immune activation profile following FZPDG treatment. A potential mechanism of action for FZPDG appears to lie in its ability to up-regulate CD38 and HLA-DR levels on CD4+ T cells, and down-regulate them on CD8+ cells, thereby modulating immune activation of CD4+and CD8+T cells.
authors.affiliation: AIDS Research Center, Ruikang Hospital Affiliated to Guangxi University of Chinese Medicine, Nanning 530011, China. jiangfengdoc@163.com
authors.forename: Feng
authors.initials: F
authors.lastname: Jiang
authors.forename: Rongxin
authors.initials: R
authors.lastname: Zhang
authors.forename: Zhenfang
authors.initials: Z
authors.lastname: Gu
authors.forename: Huailing
authors.initials: H
authors.lastname: Zhang
authors.forename: Huijun
authors.initials: H
authors.lastname: Guo
authors.forename: Xin
authors.initials: X
authors.lastname: Deng
authors.forename: Jian
authors.initials: J
authors.lastname: Liang
mesh_terms: D051997:ADP-ribosyl Cyclase 1 / Q000276:immunology*; D000163:Acquired Immunodeficiency Syndrome / Q000188:drug therapy* / Q000276:immunology*; D000293:Adolescent; D000328:Adult; D000368:Aged; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology*; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology; D004365:Drugs, Chinese Herbal / Q000627:therapeutic use*; D005260:Female; D005434:Flow Cytometry; D006681:HLA-D Antigens / Q000276:immunology*; D006801:Humans; D008297:Male; D008875:Middle Aged; D055815:Young Adult
chemical_list: D004365:Drugs, Chinese Herbal; D006681:HLA-D Antigens; D051997:ADP-ribosyl Cyclase 1